Comparative Pharmacology
Head-to-head clinical analysis: ORTHO CYCLEN 21 versus ORTHO NOVUM 2 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO CYCLEN 21 versus ORTHO NOVUM 2 21.
ORTHO CYCLEN-21 vs ORTHO-NOVUM 2-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norgestimate. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial structure to impair sperm penetration and implantation.
Combination of estrogen (ethinyl estradiol) and progestin (norethindrone) inhibits ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing gonadotropin release. Additionally, induces changes in cervical mucus and endometrium.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg for days 1-7, norgestimate 0.215 mg/ethinyl estradiol 0.035 mg for days 8-14, norgestimate 0.250 mg/ethinyl estradiol 0.035 mg for days 15-21) orally once daily for 21 days, followed by 7 placebo tablets (if included) or 7 drug-free days, then repeat.
One tablet orally once daily for 21 days followed by 7 days off. Each tablet contains norethindrone 2 mg and ethinyl estradiol 0.1 mg.
None Documented
None Documented
Terminal elimination half-life: Norgestimate metabolite (norelgestromin) ~28 hours; Ethinyl estradiol ~17 hours (range 13-27 hours). Clinical context: Steady-state achieved within 10-14 days.
Norethindrone: terminal half-life 5-12 hours; ethinyl estradiol: terminal half-life 7-20 hours (enterohepatic recirculation may prolong effect). Steady-state achieved after 5-7 days.
Approximately 40% renal (as metabolites), 60% biliary/fecal (as metabolites). Norgestimate metabolites are excreted primarily in urine (40-50%) and feces (50-60%). Ethinyl estradiol metabolites are excreted in urine (40%) and feces (60%).
Renal (approx. 60% as metabolites), fecal (approx. 40% as metabolites). Norethindrone and ethinyl estradiol are extensively metabolized; less than 5% excreted unchanged in urine.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive